Purple Biotech (PPBT) has released an update.
Purple Biotech has presented promising interim data from a Phase 2 study, suggesting that their lead oncology therapeutic candidate CM24, in combination with nivolumab and chemotherapy, may improve overall survival in pancreatic cancer patients. The study has identified potential biomarkers that could guide future patient selection for CM24-based therapy and has shown a reduction in serum NET levels, indicating a new mechanism of action for the treatment. These findings, showcased at a recent AACR Special Conference, bolster the potential of CM24 in treating multiple cancer types by targeting CEACAM1, a key player in tumor progression and immune evasion.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
